# Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.

> **NCT00871000** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 303 (actual)

## Conditions studied

- Acellular Pertussis
- Tetanus
- Diphtheria
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Boostrix Polio™ 711866
- **BIOLOGICAL:** Priorix Tetra TM 208136
- **BIOLOGICAL:** Tetravac TM

## Key facts

- **NCT ID:** NCT00871000
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-01
- **Primary completion:** 2009-11-18
- **Final completion:** 2009-11-18
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871000, "Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00871000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*